Main Article Content
Heart failure with reduced ejection fraction (HFrEF) remains burdensome because its morbidity and mortality is still relatively high. The current treatments implementing multiple drugs for controlling symptoms and reduced fatal event have been proposed, however the mortality rate remains constant. Sodium-glucose cotransporter-2 (SGLT2) inhibitor, a novel class of drugs, had been introduced as a new pillar for HFrEF treatment. The DAPA-HF trial showed the beneficial impression of dapagliflozin, an SGLT2 inhibitor, on reducing the risk of hospitalization and mortality in HFrEF patients with or without type 2 diabetes mellitus.